Recent Updates
Recently added Catalysts

ADP-A2AFP

Phase 1

Hepatocellular Cancer | Gene therapy | Oncology |Adaptimmune Therapeutics PLC Sponsored ADR|Last Updated: Aug 15, 2025

Target and mechanism

ModalityGene therapy

Also known as Autologous genetically modified AFPᶜ³³²T cells

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment45

FDA Designations

No designations recorded

Clinical trial landscape

ADP-A2AFP · 1 trial · 2 indications

Phase 1 1
NCT03132792AFPᶜ³³²T in Advanced HCCHepatocellular Cancer
ACTIVE NOT_RECRUITING45 Analytics
PHASE1ACTIVE NOT_RECRUITING
AFPᶜ³³²T in Advanced HCC
Hepatocellular Cancer
NCT0313279245
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).
2 years

Determine if treatment with autologous genetically modified T cells, (AFPᶜ³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin

Secondary Endpoints

Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR)
2 years
Interval between the date of first T cell infusion dose and first documented evidence of CR or PR
2 years
Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause
2 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Autologous genetically modified AFPᶜ³³²T cellsEXPERIMENTAL -

Interventions

NameTypeDescription
Autologous genetically modified AFPᶜ³³²T cellsGENETICInfusion of autologous genetically modified AFPᶜ³³²T cells
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites21

Key Inclusion Criteria: 1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations. 2. Histologically confirmed HCC, not amenable to transplant, resection. Subject...

Countries:United StatesFranceSpainUnited Kingdom
Unlock Eligibility Criteria